Potential treatment paradigms for anxiety disorders

Expert Opinion on Investigational Drugs

Volumn 8, Issue 10, 1999, Pages 1589-1598

  Millet, B ^a   Andre, C ^a   Deligne, H ^a   Olie, J P ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Antidepressants; Anxiety disorders; Benzodiazepines; CCK antagonists; Norepinephrine; Pharmacological treatments; Serotonin blockers; Serotonin reuptake inhibitors

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; BUSPIRONE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; GEPIRONE; HYDROXYZINE; IMIPRAMINE; IPSAPIRONE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; UNINDEXED DRUG; VENLAFAXINE;

ACUTE DISEASE; ANXIETY NEUROSIS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DROWSINESS; DRUG DEPENDENCE; DRUG EFFICACY; HUMAN; MOTOR DYSFUNCTION; OBSESSION; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SOCIAL PHOBIA; SYMPTOM;

EID: 0032872286     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.10.1589     Document Type: Review

References (49)